Interruption of BCG Therapy for NMIBC During COVID-19 Crisis, Dilemma in Its Continuation: a Review of Available Evidence and Suggested Management Strategies
Tóm tắt
The COVID-19 disease, caused by SARS-CoV-2 virus, has been one of the worst pandemics ever to hit the human mankind. Undoubtedly the start of the second wave of COVID-19 has literally ripped apart the hearts of millions of people. Cancer patients have been left of the beaten track to their fate, with no access to treatments. Intravesical BCG instillation is the standard of care for patients with non-muscle invasive bladder cancer (NMIBC). Several patients were in the middle of their treatment regimen when this pandemic struck. As slowly the word is recuperating from concussion effect of this pandemic and routine health services are being restored, uro-oncologist will face a unique scenario with respect to intravesical BCG therapy i.e., whether to restart the course of BCG therapy or to continue course from where it was interrupted. There are no studies in literature to directly answer this peculiar question and to resolve this dilemma. So, we in this review article propose to explore the literature for the most appropriate therapeutic regimen for these patients with interruption of intravesical BCG therapy. We plan to divide the patients with interruption to BCG therapy into the following three groups: We will compile the recent recommendations by NCCN, AUA, and EAU for the administration of intravesical BCG in non-muscle invasive bladder cancer. We herein want to review the literature to propose the most appropriate strategy, its safety profile for these subsets of patients.
Tài liệu tham khảo
citation_journal_title=Int J Surg; citation_title=World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19); citation_author=C Sohrabi, Z Alsafi, N O’Neill, M Khan, A Kerwan, A Al-Jabir; citation_volume=76; citation_publication_date=2020; citation_pages=71-76; citation_doi=10.1016/j.ijsu.2020.02.034; citation_id=CR1
citation_journal_title=Eur Urol; citation_title=European Association of Urology Guidelines Office Rapid Reaction Group: an organisation-wide collaborative effort to adapt the European Association of Urology Guidelines recommendations to the coronavirus disease 2019 Era; citation_author=M Ribal, P Cornford, A Briganti, T Knoll, S Gravas, M Babjuk; citation_volume=78; citation_issue=1; citation_publication_date=2020; citation_pages=21-28; citation_doi=10.1016/j.eururo.2020.04.056; citation_id=CR2
citation_journal_title=J Urol; citation_title=Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors; citation_author=A Morales, D Eidinger, A Bruce; citation_volume=116; citation_issue=2; citation_publication_date=1976; citation_pages=180-182; citation_doi=10.1016/S0022-5347(17)58737-6; citation_id=CR3
citation_journal_title=Vaccine; citation_title=In vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCG; citation_author=MM Venkataswamy, MF Goldberg, A Baena, J Chan, WR Jacobs, SA Porcelli; citation_volume=30; citation_issue=6; citation_publication_date=2012; citation_pages=1038-1049; citation_doi=10.1016/j.vaccine.2011.12.044; citation_id=CR4
citation_journal_title=Tuber Lung Dis; citation_title=Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree; citation_author=T Oettinger, M Jorgensen, A Ladefoged, K Haslov, P Andersen; citation_volume=79; citation_issue=4; citation_publication_date=1999; citation_pages=243-250; citation_doi=10.1054/tuld.1999.0206; citation_id=CR5
citation_journal_title=Lancet; citation_title=BCG immunotherapy of bladder cancer: 20 years on; citation_author=A Alexandroff, A Jackson, M O’Donnell, K James; citation_volume=353; citation_issue=9165; citation_publication_date=1999; citation_pages=1689-1694; citation_doi=10.1016/S0140-6736(98)07422-4; citation_id=CR6
citation_journal_title=Cancer Sci; citation_title=Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine; citation_author=K Kawai, J Miyazaki, A Joraku, H Nishiyama, H Akaza; citation_volume=104; citation_issue=1; citation_publication_date=2013; citation_pages=22-27; citation_doi=10.1111/cas.12075; citation_id=CR7
Green J, Fuge O, Allchorne P, Vasdev N (2015) Immunotherapy for bladder cancer. Res Rep Urol 65.
citation_journal_title=Rev Urol; citation_title=Intravesical therapy for non-muscle invasive bladder cancer-current and future options in the age of Bacillus Calmette-Guerin shortage; citation_author=V Golla, AT Lenis, I Faiena, K Chamie; citation_volume=21; citation_issue=4; citation_publication_date=2019; citation_pages=145-153; citation_id=CR9
Green J, Fuge O, Allchorne P, Vasdev N (2015) Immunotherapy for bladder cancer. Res Rep Urol 65.
citation_journal_title=J Oncol Pract; citation_title=Adjuvant intravesical Bacillus Calmette-Guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer; citation_author=BA Spencer, RB McBride, DL Hershman; citation_volume=9; citation_publication_date=2013; citation_pages=92-98; citation_doi=10.1200/JOP.2011.000480; citation_id=CR11
citation_journal_title=J Urol; citation_title=Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline; citation_author=S Chang, S Boorjian, R Chou, P Clark, S Daneshmand, B Konety; citation_volume=196; citation_issue=4; citation_publication_date=2016; citation_pages=1021-1029; citation_doi=10.1016/j.juro.2016.06.049; citation_id=CR12
Non-muscle-invasive bladder cancer – introduction – Uroweb. In: Uroweb – European Association of Urology. Uroweb.
https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
. Accessed 31 Dec 2022.
citation_journal_title=J Natl Compr Cancer Netw; citation_title=Bladder cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology; citation_author=T Flaig, P Spiess, N Agarwal, R Bangs, S Boorjian, M Buyyounouski; citation_volume=18; citation_issue=3; citation_publication_date=2020; citation_pages=329-354; citation_doi=10.6004/jnccn.2020.0011; citation_id=CR14
citation_journal_title=J Urol; citation_title=Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study; citation_author=DL Lamm, BA Blumenstein, JD Crissman; citation_volume=163; citation_issue=4; citation_publication_date=2000; citation_pages=1124-9; citation_doi=10.1016/S0022-5347(05)67707-5; citation_id=CR15
citation_journal_title=Exp Ther Med; citation_title=Monthly intravesical Bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute; citation_author=K Yoo, T Lim, S Chang; citation_volume=3; citation_issue=2; citation_publication_date=2011; citation_pages=221-225; citation_doi=10.3892/etm.2011.400; citation_id=CR16
citation_journal_title=Int J Clin Oncol; citation_title=Single monthly Bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer; citation_author=T Okamura, H Akita, R Ando, Y Ikegami, T Naiki, N Kawai; citation_volume=17; citation_issue=5; citation_publication_date=2011; citation_pages=477-481; citation_doi=10.1007/s10147-011-0314-3; citation_id=CR17
citation_journal_title=Urol Ann; citation_title=Monthly maintenance protocol Bacillus Calmette-Guerin as a viable alternative to Southwest Oncology Group maintenance protocol in nonmuscle-invasive bladder cancer: A prospective randomized study; citation_author=D Sarkar, N Gupta, D Pal; citation_volume=12; citation_issue=2; citation_publication_date=2020; citation_pages=116; citation_doi=10.4103/UA.UA_29_19; citation_id=CR18
Davies B (2016) Sanofi shuts down bladder cancer drug production: inevitable drug shortage to harm patients. In: Forbes.
https://www.forbes.com/sites/benjamindavies/2016/11/17/sanofi-shuts-down-bladder-cancer-drug-production-inevitable-drug-shortage-to-harm-patients/
. Accessed 31 Dec 2022
Palmer E (2016) Sanofifi discontinuing bladder cancer drug TheraCys after years of production issues. In: FiercePharma.
https://www.fifiercepharma.com/manufacturing/sanofifi-discontinuing-bladder-cancer-drug-teracys-after-years-production-issues
. Accessed 31 Dec 2022
citation_journal_title=J Urol; citation_title=Triaging office-based urology procedures during the COVID-19 pandemic; citation_author=EG Katz, KS Stensland, A Jessica, LS Maclachlan, A Moinzadeh; citation_volume=204; citation_publication_date=2020; citation_pages=9-10; citation_doi=10.1097/JU.0000000000001034; citation_id=CR21
citation_journal_title=J Glob Oncol; citation_title=Alternative therapies to Bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer in Brazil and other underdeveloped countries: management considerations; citation_author=ML Wroclawski, FA Schutz, JD Cha, A Soares; citation_volume=5; citation_publication_date=2019; citation_pages=1-9; citation_id=CR22
Covid-19 recommendations by EAU guidelines panels. In: Uroweb.
https://uroweb.org/news/covid-19-recommendations-by-eau-guidelines
. Accessed 31 Dec 2022
citation_journal_title=Turk J Urol; citation_title=Intravesical BCG amid COVID-19: to give or not to give?; citation_author=E Desouky; citation_volume=46; citation_issue=4; citation_publication_date=2020; citation_pages=274-276; citation_doi=10.5152/tud.2020.20206; citation_id=CR24
Powell M (2020) Bladder cancer treatment options | BCAN. In: Bladder Cancer Advocacy Network.
https://bcan.org/covid-19-faq/
. Accessed 31 Dec 2022
citation_journal_title=J Urol; citation_title=Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors; citation_author=A Morales, D Eidinger, A Bruce; citation_volume=116; citation_issue=2; citation_publication_date=1976; citation_pages=180-182; citation_doi=10.1016/S0022-5347(17)58737-6; citation_id=CR26
citation_journal_title=Cancer Immunol Immunother; citation_title=Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with Bacillus Calmette-Guérin in superficial bladder cancer; citation_author=E Boer, W Jong, P Steerenberg, L Aarden, E Tetteroo, E Groot; citation_volume=34; citation_issue=5; citation_publication_date=1992; citation_pages=306-312; citation_doi=10.1007/BF01741551; citation_id=CR27
citation_journal_title=Ecancermedicalscience; citation_title=The use of intravesical BCG in urothelial carcinoma of the bladder; citation_author=O Alhunaidi, AR Zlotta; citation_volume=13; citation_publication_date=2019; citation_pages=905; citation_doi=10.3332/ecancer.2019.905; citation_id=CR28
citation_journal_title=J Immunother Cancer; citation_title=Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma; citation_author=A Kamat, J Bellmunt, M Galsky, B Konety, D Lamm, D Langham; citation_volume=5; citation_issue=1; citation_publication_date=2017; citation_pages=68; citation_doi=10.1186/s40425-017-0271-0; citation_id=CR29
citation_journal_title=Eur Urol; citation_title=What is the optimal regimen for BCG intravesical therapy?; citation_author=A Zlotta, J Vooren, K Huygen, A Drowart, M Decock, M Pirson; citation_volume=37; citation_issue=4; citation_publication_date=2000; citation_pages=470-477; citation_doi=10.1159/000020170; citation_id=CR30
citation_journal_title=Eur Urol; citation_title=Treatment of high-grade non–muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”; citation_author=M Grimm, A Heijden, M Colombel, T Muilwijk, L Martínez-Piñeiro, M Babjuk; citation_volume=78; citation_issue=5; citation_publication_date=2020; citation_pages=690-698; citation_doi=10.1016/j.eururo.2020.04.066; citation_id=CR31
citation_journal_title=Eur Urol; citation_title=Adjustments in the use of intravesical instillations of Bacillus Calmette-Guérin for high-risk non-muscle-invasive bladder cancer during the COVID-19 pandemic; citation_author=L Lenfant, T Seisen, Y Loriot, M Rouprêt; citation_volume=78; citation_issue=1; citation_publication_date=2020; citation_pages=1-3; citation_doi=10.1016/j.eururo.2020.04.039; citation_id=CR32
citation_journal_title=J Urol; citation_title=Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials; citation_author=RJ Sylvester, MA Van der, DL Lamm; citation_volume=168; citation_publication_date=2002; citation_pages=1964-70; citation_doi=10.1016/S0022-5347(05)64273-5; citation_id=CR33
citation_journal_title=Jpn J Clin Oncol; citation_title=Maintenance therapy with intravesical Bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer; citation_author=S Muto, A Nakajima, A Horiuchi, M Inoue, T China, K Saito; citation_volume=43; citation_issue=3; citation_publication_date=2013; citation_pages=305-313; citation_doi=10.1093/jjco/hys225; citation_id=CR34
citation_journal_title=Eur Urol; citation_title=Final results of an EORTC-GU Cancers Group randomized study of maintenance Bacillus Calmette-Guerin in intermediate and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one third dose versus full dose and 1 year versus 3 years of maintenance; citation_author=J Oddens, M Brausi, R Sylvester; citation_volume=63; citation_publication_date=2013; citation_pages=462-472; citation_doi=10.1016/j.eururo.2012.10.039; citation_id=CR35
citation_journal_title=Cancer; citation_title=Maintenance Bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer; citation_author=M Decobert, H LaRue, F Harel, F Meyer, Y Fradet, L Lacombe; citation_volume=113; citation_issue=4; citation_publication_date=2008; citation_pages=710-716; citation_doi=10.1002/cncr.23627; citation_id=CR36